Indication

To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).

Medicine details

Medicine name:
solriamfetol (Sunosi)
SMC ID:
SMC2419
Pharmaceutical company
Jazz Pharmaceuticals
BNF chapter
Central nervous system
Submission type
Full
Publication due date:
14 March 2022
SMC meeting date:
01 February 2022
Patient group submission deadline:
13 December 2021